Using a proazaphosphatranecatalyst, P(RNCH2CH2)3N (R=Me, i-Pr), allylaromatics and allylphenyl sulfide were selectively isomerized to the corresponding vinyl isomers in yields up to >99% in CH3CN at 40 °C. Efficient transformation of allylphenylsulfone at ambient temperature afforded an isomerization/dimerization product in >95% yield. Conjugation of bis-allylmethylene double bond-containing compounds
A Highly Active Cationic Ruthenium Complex for Alkene Isomerisation: A Catalyst for the Synthesis of High Value Molecules
作者:Simone Manzini、David J. Nelson、Steven P. Nolan
DOI:10.1002/cctc.201300396
日期:2013.10
You′ve been valorized! A novel cationic ruthenium complex is shown to be efficient in the isomerization of important feedstocks derived from essential oils, which can then be functionalized through olefin metathesis.
[EN] NOVEL CYCLIC PHENOXY COMPOUNDS AND IMPROVED TREATMENTS FOR CARDIAC AND CARDIOVASCULAR DISEASE<br/>[FR] NOUVEAUX COMPOSÉS PHÉNOXY CYCLIQUES ET TRAITEMENTS AMÉLIORÉS POUR UNE MALADIE CARDIAQUE ET CARDIOVASCULAIRE
申请人:UNIV NOTTINGHAM
公开号:WO2013121209A1
公开(公告)日:2013-08-22
A compound of formula I, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: (Formula (I)) wherein either Q1, CR6a and optionally R6b together form a cyclic moiety wherein: Q1 is selected from C1-2 alkylene, C1-2 alkenylene, OC1 alkylene and OC1 alkenylene moieties optionally substituted by oxo; R6a is a single bond and R6b is H; or R6a and R6b together form a double bond; and Q2 and Q3 are independently selected from H, R1 and R2; or Q2 and Q3 together form a cyclic moiety in which one of Q2 and Q3 is a cyclic moiety selected from OC1 alkylene and OC1 alkenylene moieties optionally substituted by oxo or a group R5 as hereinbelow defined for R2 and the other of Q2 and Q3 is a cyclic moiety selected from C1-2 alkylene, C1-2 alkenylene and OC1 alkylene optionally substituted by oxo; R6a and R6b are each H or a cyclic moiety as defined above; and Q1 is selected from H, R1 and R2 and a cyclic moiety as defined above; and R1-4 are H or substituents; Z is selected from linear C2-3 alkylene; X3 is NH; R7-9 are H or substituents; their preparation and novel intermediates, compositions thereof and their use in the prevention or treatment of cardiac and cardiovascular disease and methods for the treatment thereof.
in the sluggish RuH2(CO)(PPh3)3 catalyst, bloated PPh3 ligands cause steric hindrance for the coordination of the free alkene. Alternatively, the addition of non‐redox metal ions could induce the dissociation of the PPh3 ligand to offer unoccupied coordination sites for the alkene and to form the Mg‐bridged adduct OC−Ru−H2−Mg2+ as the highly active species, which benefited the isomerization significantly
of noble metal catalysts in homogeneouscatalysis has been well established. Due to their price and limited availability, there is growing interest in the substitution of such precious metal complexes with readily available and bio‐relevant catalysts. In particular, iron is a “rising star” in catalysis. Herein, we present a general and selective iron‐catalyzed monoisomerization of olefins, which allows